Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient-Reference-Cited by-同舟云学术

Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient

Published:2021-10-04 Issue:3 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Sheikh Irtiza¹^ORCID,Nunez Cesar¹,McCall David¹^ORCID,Roth Michael¹^ORCID,Cuglievan Branko¹

Affiliation:

1. Division of Pediatrics and Patient Care The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29390

Reference12 articles.

1. Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care

2. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma

3. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

4. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

5. Feasibility of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (< 18 years) with early relapse Hodgkin lymphoma.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances;International Journal of Molecular Sciences;2023-06-13

2. Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma;Frontiers in Cell and Developmental Biology;2022-11-24